Full Press Release Details
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in four upcoming investment bank conferences in New York.
Details
Citi Biopharma Back to School SummitSeptember 9-10, 2026
Cantor Global Healthcare ConferenceSeptember 9-11, 2026Fireside Chat with Rick Pauls (CEO) and Dr. Julie Krop (CMO), on Friday, September 11, 2026, at 10:20 a.m. ET
Lake Street 10thAnnual Best Ideas Growth (BIG10) ConferenceSeptember 10, 2026
HC Wainwright 28thAnnual Global Investment ConferenceSeptember 14-16, 2026Company presentation by Rick Pauls, CEO, on Tuesday, September 15, 2026, at 1:30 p.m. ET
If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website atwww.diamedica.com.
Scott KellenChief Financial OfficerPhone: (763) 496-5118skellen@diamedica.com